Phase 2 trial reveals significant improvement in MASH patients
Category: News
Inebilizumab shows sound efficacy in landmark research
Innovative antibody discovery could lead to new Parkinson’s treatments
Phase 3 research suggests a significant leap forward in myeloma management
Extended phase 2 study highlights macrophage cell therapy’s efficacy
Collaboration yields promising Barriolide therapy Enterothelin
Positive clinical data from phase 1 study presented at ASCO annual meeting
Bone cancer affects more than 150,000 people in the UK and is often resistant to chemotherapy
The platform will be used to diagnose and treat cancers, including lung and brain tumours
The projects will focus on a range of research areas, including Down’s syndrome and ALS